R1 RCM Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" R1 RCM stock.
View analyst ratings for R1 RCM or view top-rated stocks.

Wall Street analysts have given R1 RCM a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but R1 RCM wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for R1 RCM.

R1 RCM Inc. (NASDAQ:RCM) posted its quarterly earnings results on Tuesday, August, 3rd. The healthcare provider reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by $0.03. The healthcare provider had revenue of $353.40 million for the quarter, compared to analysts' expectations of $343.94 million. R1 RCM had a trailing twelve-month return on equity of 49.25% and a net margin of 9.61%. The company's revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.04 earnings per share.
View R1 RCM's earnings history.

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCM shares have increased by 110.0% and is now trading at $21.34.
View which stocks have been most impacted by COVID-19.

R1 RCM issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.46 billion-$1.48 billion, compared to the consensus revenue estimate of $1.45 billion.

7 analysts have issued 12 month price objectives for R1 RCM's stock. Their forecasts range from $22.00 to $35.00. On average, they expect R1 RCM's share price to reach $28.57 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts' price targets for R1 RCM or view top-rated stocks among Wall Street analysts.

253 employees have rated R1 RCM CEO Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

Some companies that are related to R1 RCM include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), Amedisys (AMED), AMN Healthcare Services (AMN), LHC Group (LHCG), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of RCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.84%), Vanguard Group Inc. (4.53%), FMR LLC (3.19%), State Street Corp (1.46%), Paradigm Capital Management Inc. NY (1.47%) and American Century Companies Inc. (1.41%). Company insiders that own R1 RCM stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Principal Financial Group Inc., Invesco Ltd., Glenmede Trust Co. NA, Bank of America Corp DE, Legal & General Group Plc, Morgan Stanley, and Morgan Stanley. Company insiders that have sold R1 RCM company stock in the last year include Achi Series Lllp Tcp-Asc, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, and Richard B Jr Evans.
View insider buying and selling activity for R1 RCM or view top insider-selling stocks.

RCM stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., American Century Companies Inc., Sunriver Management LLC, Maven Securities LTD, Point72 Asset Management L.P., Bank of New York Mellon Corp, and State Street Corp. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM or or view top insider-buying stocks.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCM stock can currently be purchased for approximately $21.34.

R1 RCM has a market capitalization of $5.95 billion and generates $1.27 billion in revenue each year. The healthcare provider earns $117.10 million in net income (profit) each year or $0.28 on an earnings per share basis.

R1 RCM employs 20,200 workers across the globe.

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Advanced Data Processing Inc., Cerner RevWorks, Intermedix, Intermedix ARM LLC, Intermedix Analytics LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Physician Services LLC, Intermedix Staffing Inc., Med Media Inc., Medical Consultants Inc., Optima (NZ) Limited, Optima (US) LTD, Practice Support Resources LLC, Project Links Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCI Solutions, The DeZonia Group Inc., The Optima Corporation (International) LTD, The Optima Corporation Limited, and The Optima Corporation PTY LTD.

R1 RCM was founded in 2003.

The official website for R1 RCM is www.r1rcm.com.

R1 RCM is headquartered at 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820 or via email at [email protected].